➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
AstraZeneca
Mallinckrodt
Merck
Dow

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,312,237

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,312,237 protect, and when does it expire?

Patent 7,312,237 protects IXEMPRA KIT and is included in one NDA.

Protection for IXEMPRA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in twenty-six countries.

Summary for Patent: 7,312,237
Title:Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Abstract:Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Inventor(s): Lee; Francis Y. F. (Yardley, PA)
Assignee: Bristol-Myers Squibb Co. (Princeton, NJ)
Application Number:10/091,061
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 7,312,237

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-001 Oct 16, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;INTRAVENOUS 022065-002 Oct 16, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,312,237

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 554756   Start Trial
Australia 2002248542   Start Trial
Bulgaria 108137   Start Trial
Bulgaria 66289   Start Trial
Brazil 0207961   Start Trial
Brazil PI0207961   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKinsey
Dow
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.